OncoSec Medical (NASDAQ:ONCS) Cut to “Sell” at StockNews.com

StockNews.com lowered shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) from a hold rating to a sell rating in a research report released on Tuesday morning.

OncoSec Medical Trading Down 4.3 %

Shares of OncoSec Medical stock opened at $0.51 on Tuesday. The stock has a 50-day moving average price of $1.26 and a 200 day moving average price of $2.65. The company has a market cap of $1.52 million, a P/E ratio of -0.03 and a beta of 1.99. OncoSec Medical has a 1 year low of $0.47 and a 1 year high of $20.68.

OncoSec Medical (NASDAQ:ONCS – Get Rating) last posted its quarterly earnings results on Monday, March 13th. The biotechnology company reported ($2.65) earnings per share for the quarter.

Institutional Investors Weigh In On OncoSec Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its stake in shares of OncoSec Medical by 653.7% during the 1st quarter. Bank of New York Mellon Corp now owns 386,074 shares of the biotechnology company’s stock worth $444,000 after purchasing an additional 334,849 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in shares of OncoSec Medical during the 1st quarter valued at about $272,000. Renaissance Technologies LLC increased its holdings in shares of OncoSec Medical by 48.8% during the 2nd quarter. Renaissance Technologies LLC now owns 72,898 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 23,900 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in shares of OncoSec Medical during the 4th quarter valued at about $35,000.

OncoSec Medical Company Profile

(Get Rating)

OncoSec Medical, Inc is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor.